Publication | Closed Access

Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial

Phase 1/2Hematological MalignancyOncologyMedicineHematologyPharmacotherapyPharmacologyChemotherapyCancer ResearchMyeloid Neoplasia